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Abstract 
Opioid analgesics are the standards of care for the treatment of moderate to severe nociceptive 
pain, particularly in the setting of cancer and surgery. Their analgesic properties mainly emanate from 
stimulation of the μ receptors, which are encoded by the OPRM1 gene. Hepatic metabolism represents 
the major route of elimination, which, for some opioids, namely codeine and tramadol, is necessary for 
their bioactivation into more potent analgesics. The highly polymorphic nature of the genes coding for 
phase I and phase II enzymes (pharmacokinetics genes) that are involved in the metabolism and 
bioactivation of opioids suggests a potential interindividual variation in their disposition and, most 
likely, response. In fact, such an association has been substantiated in several pharmacokinetic studies 
described in this review, in which drug exposure and/or metabolism differed significantly based on the 
presence of polymorphisms in these pharmacokinetics genes. Furthermore, in some studies, the 
observed variability in drug exposure translated into differences in the incidence of opioid-related 
adverse effects, particularly nausea, vomiting, constipation, and respiratory depression. Although the 
influence of polymorphisms in pharmacokinetics genes, as well as pharmacodynamics genes (OPRM1 
and COMT) on response to opioids has been a subject of intense research, the results have been 
somehow conflicting, with some evidence insinuating for a potential role for OPRM1. The Clinical 
Pharmacogenetics Implementation Consortium guidelines provide CYP2D6-guided therapeutic 
recommendations to individualize treatment with tramadol and codeine. However, implementation 
guidelines for other opioids, which are more commonly used in real-world settings for pain 
management, are currently lacking. Hence, further studies are warranted to bridge this gap in our 
knowledge base and ultimately ascertain the role of pharmacogenetic markers as predictors of 
response to opioid analgesics.  
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Introduction 
Interpatient variability in medication response is a well-known phenomenon. Certain patients 
respond as expected to certain therapies, whereas others do not respond at all or experience adverse 
effects. This variation in response is due to clinical and environmental factors such as age, body weight, 
renal or hepatic function, comorbidities, and concomitant medications. Over the last several decades, 
genetic polymorphisms have been proven to be one of the main culprits of medication response 
variability.
(1)
 Pharmacogenetics—the study of the influence of genetic variants on medication 
response—has been directly implicated in the management of many medical conditions, including pain. 
Clinical pain management currently involves the use of nonpharmacologic methods and many 
pharmacologic agents including opioids, nonsteroidal antiinflammatory drugs, antidepressants, and 
anticonvulsants. Regardless of the available treatment modalities, complete pain relief is still an elusive 
concept to many patients. It has been observed that 38–74% of patients with cancer experience 
inadequate pain relief regardless of the management strategy used.
2( )
 In a national survey involving 250 
randomly selected postoperative adult patients, 80% expressed inadequate postoperative pain relief.
3( )
For centuries, opioid analgesics have been used to manage moderate to severe acute and 
chronic pain. They are generally safe; however, in certain patients they produce adverse effects such as 
respiratory depression, sedation, nausea, vomiting, constipation, impaired cognition, and sometimes 
even death.
 
These findings and many others highlight the need for pain management optimization, regardless of 
patients’ comorbidities, to ensure maximum efficacy while preventing and/or minimizing toxicity.  
(4-6)
 Moreover, there are subsets of patients who may not experience the analgesic 
properties of opioids.
7( )
 Genetic polymorphisms have been labeled as some of the main culprits of 
opioid response variation. In recent years, several genetic testing companies have developed pain-
specific pharmacogenetic panels to help clinicians address this concern. These panels interrogate a 
number, if not all, of the genes discussed in this review article.  To address the clinical utility of these 
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drug-gene pairs, we conducted a search of the PubMed database for original studies involving human 
subjects using medical subject heading terms consisting of each opioid’s drug name, pharmacogenetics, 
pharmacogenomics, and polymorphisms, and the terms pharmacokinetics, disposition, response, 
efficacy, adverse events, side effects, and toxicity. Relevant references from the selected articles as well 
as resources available on www.pharmgkb.org for each of the opioid medications were reviewed and 
included where applicable. This review focuses on the pharmacogenetics of opioids and their readiness 
for adoption into clinical practice.   
 
Overview of Opioids 
Metabolic Pathways and Pharmacology  
Opioid receptors are present in both the central nervous system (CNS) as well as peripheral 
tissues throughout the body. Three receptors are largely responsible for the opioid mechanisms of 
analgesia and adverse effect profiles: μ, κ, and δ receptors.(8) Several subtypes of each receptor exist 
and are denoted by numbers after the receptor type (e.g., μ1
8
). μ-Receptor activation leads to 
supraspinal analgesia and well-known opioid adverse effects (respiratory depression, sedation, 
euphoria, and decreased gastrointestinal motility). The gene coding for the μ receptors, OPRM1, is 
highly polymorphic, with more than 100 variants identified. One of the most studied alleles is the 118 
A>G polymorphism (rs1799971), with a prevalence ranging from 2-48%. κ-Receptor activation leads to 
spinal analgesia and similar adverse effects (respiratory depression, sedation, and dysphoria). δ-
Receptor agonism likely leads to dysphoria and psychomimetic effects. All opioids are μ-receptor 
agonists and vary in their degree of κ and δ agonism. Some opioids, such as tramadol and methadone, 
have additional nonopioid receptor–based sites of action.
( )
 
  
Drug Metabolism and Disposition 
Opioid analgesics are extensively metabolized in the liver. The metabolic pathway of each agent 
is quite complex and generally entails both phase I and phase II enzymes. Almost all of the phase I 
enzymes involved in opioid metabolism belong to the cytochrome P450 (CYP) family (mainly CYP2D6, 
CYP3A4/CYP3A5), whereas the phase II enzymes include the uridine diphosphoglucuronysyltransferases 
(UGTs). Phase I metabolism results in either active or inactive metabolites, with many active 
metabolites possessing more potent activity than their parent drug.
(9, 10)
 The complete metabolic 
pathways of the opioids are described in Figure 1. Given the polymorphic nature of the genes coding for 
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these enzymes, regardless of whether they are phase I or phase II enzymes, it is reasonable to assume 
that a significant variation in drug disposition or pharmacokinetics exists among individuals taking these 
medications for analgesia. This topic has garnered much interest among investigators in light of the 
improved understanding of human genetics coupled with the advances made in the field of molecular 
technology. In fact, several studies sought to interrogate the association between polymorphisms in 
pharmacogenes and interindividual differences in opiate plasma concentration or exposure. Findings 
from some of these studies will be highlighted in the following sections. However, the critical question is 
whether the reported variability in drug exposure translates into differences in drug efficacy and 
incidence of adverse effects. In this review, we describe the effects of various genes on the disposition, 
efficacy, and toxicity profiles of individual opioids and comment on whether these associations are 
mature for adoption into clinical practice.  
 
Codeine 
Impact of Genetic Polymorphisms on Codeine Disposition 
Codeine is a prodrug that undergoes O-demethylation into morphine. This process is mediated 
by CYP2D6 and it accounts for about 10% of the overall elimination pathway of codeine. CYP2D6 is a 
highly polymorphic gene that is responsible for the metabolism of approximately 25% of all commonly 
prescribed medications. To date, approximately 100 CYP2D6 variants have been identified, which 
primarily result from single nucleotide polymorphisms (SNPs), nucleotide insertions/deletions (indels), 
or even whole gene deletion, duplication, or multiplication (copy number variations).
(11)
 As a 
consequence of these polymorphisms, CYP2D6 enzymatic activity differs among individuals. Those 
harboring two loss of function variants, as outlined in Table 1, are referred to as CYP2D6 poor 
metabolizers (PMs). CYP2D6 poor metabolizers produce low plasma concentrations of morphine and 
most likely do not derive any clinical benefit from codeine. On the opposite end of the CYP2D6 activity 
spectrum are individuals who carry at least three normal function variants (known as ultrarapid 
metabolizer [UM] phenotype), who in fact may have supratherapeutic levels of morphine. Several 
pharmacokinetic studies demonstrated a significant correlation between CYP2D6 activity and morphine 
exposure. In the study by Kircheiner et al. 
12( )
, 26 healthy male volunteers were given a single dose of 
codeine 30 mg. There was at least a 20-fold increase in morphine’s area under the curve (AUC) in 
individuals with the CYP2D6 normal metabolizer (NM [previously referred to as extensive metabolizer 
(EM)]) (11 mcg•hr/L) and the UM (16 mcg•hr/L) phenotypes relative to individuals with the PM 
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phenotype (0.5 mcg•hr/L, p=0.02). Furthermore, the codeine to morphine ratio was about 10 times 
higher in PMs (198, interquartile range [IQR] 143-599) compared to NMs (19, IQR 9.9-28) and UMs (17, 
IQR 13-19).  
 
Impact of Genetic Polymorphisms on Response to Codeine 
In addition to variation in codeine disposition, polymorphisms in CYP2D6 
(13-15)
and UGT2B7 
16( )
 
have been documented to influence codeine’s analgesic response. Moreover, in a nested cohort of 98 
postcesarean section women prescribed codeine, Baber and colleagues concluded that the OPRM1 G 
variant (118 A>G) was significantly associated with the differences in mean dose consumption (p = 
0.001).
16( )
 
 Unlike variants in ABCB1, COMT, and CYP2D6, patient-specific factors such as age and race-
ethnicity were found to be determinants of codeine variability in this study.  
Impact of Genetic Polymorphisms on Codeine Toxicity Profile 
 There are several published reports documenting the unfortunate impact of genetic 
polymorphisms on codeine therapy.
(4, 6, 17, 18)
 In a case-control study that sought to determine the 
characteristics of mothers and infants with and without CNS depression after codeine therapy, high 
codeine dose, as well as CYP2D6 UM phenotype and UGT2B7*2/*2 genotypes were found to be risk 
factors for neonatal toxicity following maternal codeine use.
4( )
 Additionally, there is a single case report 
of a 29-month-old patient who was found to have the UM phenotype for CYP2D6 after he developed 
apnea from codeine therapy.
18( )
 The patient had a scheduled adenotonsillectomy with a history of mild 
to moderate sleep apnea. On postoperative day 1, it was reported that the patient received four doses 
of codeine with acetaminophen and an additional dose on the second evening after surgery. Four hours 
later, the child was found unresponsive and apneic. The child was determined to be a CYP2D6 UM, 
which is likely a significant contributor to the apneic episode. Moreover, there is another documented 
case of a 14-year-old female who presented to the emergency department with irritability and 
drowsiness after taking acetaminophen-codeine for hip pain.
17( )
 
 The patient was determined to have a 
CYP2D6*4/*5 genotype, indicating a PM phenotype, and thereby poor codeine metabolism. In this case, 
the presenting symptoms were likely due to uncontrolled pain caused by little to no conversion of 
codeine to morphine.  
Clinical Adoption of Codeine Pharmacogenetics 
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Of all the opioids discussed in this review, codeine-CYP2D6 is the only example that has a 
dedicated Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline 
(19, 20)
  and, as such, 
has risen to clinically actionable status as seen in Figure 2. This is chiefly due to the serious nature of the 
toxicities attributed to genetics, particularly CYP2D6 polymorphisms among young codeine users.  In 
these guidelines, it is strongly recommended that CYP2D6 UMs and PMs should avoid codeine due to 
the increased risk of toxicities and lack of analgesic effects, respectively. A CPIC moderate 
recommendation for CYP2D6 IMs advises to avoid codeine after a failed initial attempt. CYP2D6 NMs 
can be prescribed codeine at the label-recommended doses. Moreover, the United States Food and 
Drug Administration (FDA) recently updated its safety warning for codeine and tramadol. This newest 
safety announcement contraindicates the use of codeine either for pain or cough in those younger than 
12 years.
21( )
 
 They also warn against the use of codeine in obese adolescents (between 12 and 18 years 
old) or those with obstructive sleep apnea or severe lung disease. Codeine is also not recommended in 
breastfeeding mothers according to this newest safety notice due to the reasons discussed above in the 
case reports. 
Fentanyl 
Impact of Genetic Polymorphisms on Fentanyl Disposition 
Fentanyl is metabolized by the polymorphic CYP3A4 and CYP3A5 enzymes (Figure 1), and 
because of that, it is expected that the metabolism of fentanyl varies among individuals. Indeed, the 
study by Takashina et al. investigated the impact of polymorphisms in the CYP3A5 (CYP3A5*3) as well as 
the ABCB1 (1236 C>T, 2677 G>A/T, and 3435 C>T) genes on fentanyl metabolism.
(5)
 
 The study recruited 
60 adult patients with cancer who received transdermal fentanyl at doses ranging from 25-75 mcg/hour 
based on their daily consumption of morphine or oxycodone. The median plasma concentration of 
fentanyl was approximately twice as high in CYP3A5*3 homozygotes (1.72 [IQR 0.91-2.31] ng/mL) 
compared to CYP3A5*1 carriers (*1/*3: 0.84 [IQR 0.76-1.17] ng/mL, and *3/*3: 0.78 [IQR 0.74-0.87] 
ng/mL, p<0.05 for both comparisons). In addition, patients with the *1/*1 and *1/*3 genotypes had at 
least a 2-fold increase in fentanyl clearance compared with CYP3A5*3 homozygotes (*1/*1: 67.4 [IQR 
47.2-78.2] L/hr, *1/*3: 58.4 [IQR 41.3-75.6] L/hr, and *3/*3: 28 [IQR 20.6-55.1] L/hr, p<0.03 for both 
comparisons).  
Impact of Genetic Polymorphisms on Response to Fentanyl 
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Landau et al. conducted a prospective observational study to discern the role of OPRM1 (118 
A>G) and COMT (Val158Met, G>A) polymorphisms with regard to analgesic response to intravenous (IV) 
fentanyl among 106 female patients in labor pain.
(22)
 The analgesic success rate, defined as numerical 
verbal pain score ≤ 10/100 15 minutes after administration of IV fentanyl, was not significantly different 
by OPRM1 genotypes (20% for AA vs 21% for AG/GG genotypes, p=0.82) or by COMT genotypes [10% 
for Met/Met vs 22% for Val/Met and Val/Val], p=0.24). The authors attributed these negative findings 
to the small sample size and suggested that larger studies are warranted to uncover the role of these 
polymorphisms in COMT and OPRM1.  In other studies, investigators have reported the involvement of 
OPRM1 in the therapeutic response variability observed with fentanyl 
23( , 24)
 and alfentanil 
25( )
. Also, in a 
study of 60 Japanese patients with cancer treated with transdermal fentanyl, Takashina et al. reported 
that patients with the ABCB1 1236TT allele were less likely to need rescue medication compared to 
carriers of 1236C allele (odds ratio 0.17, 95% confidence interval 0.03–0.89; p = 0.036).
5( )
 
 Hence, 
variants in OPRM1 and ABCB1 may be predictors of fentanyl response.  
Impact of Genetic Polymorphisms on Fentanyl Toxicity Profile 
As described earlier in the Takashina et al. study, when investigating the influence of ABCB1 and 
CYP3A5 polymorphisms on the fentanyl pharmacokinetics and response, no statistically significant 
findings were reported for fentanyl-related adverse effects and genetic polymorphisms.
(5)
 
 In ABCB1 
2677G allele carriers, there was a higher incidence of nausea and vomiting (p=0.16), whereas 3435C 
carriers had higher rates of constipation (p=0.26).  Central adverse effects were reported in more 
patients with CYP3A5*3/*3 than those with *1/*1 and *1/*3 (p=0.07). The small sample size of this 
study is most likely why these outcomes did not reach statistical significance. Further studies are 
needed to validate this theory. 
Clinical Adoption of Fentanyl Pharmacogenetics 
Fentanyl pharmacogenetics is currently not ready for clinical adoption due to lack of consistent 
data, as shown in Figure 2. The most promising evidence seems to be the influence of OPRM1 
polymorphisms on fentanyl response variations; however, these associations have not been consistently 
replicated. Variants in CYP3A5 have been observed to play a role in fentanyl disposition, but whether 
this link with fentanyl’s pharmacokinetics translates into differences in response and toxicity is yet to be 
determined.  
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Hydrocodone 
Impact of Genetic Polymorphisms on Hydrocodone Disposition 
Hydrocodone is a semisynthestic opioid that is structurally related to codeine. Hydrocodone 
undergoes extensive metabolism by CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone, 
respectively, which are further conjugated by UGTs into water-soluble metabolites that are primarily 
excreted by the kidneys. The affinity of hydromorphone for the μ receptors is at least 100-fold greater 
than that of hydrocodone. The study by Stauble et al. sought to assess the impact of polymorphisms in 
CYP2D6 on hydrocodone metabolism in female patients who underwent cesarean section.
(26)
 
 Patients 
with the CYP2D6 UM phenotype had approximately a 10-fold increase in the plasma concentration of 
hydromorphone compared to individuals with the CYP2D6 PM phenotype (7.06 vs. 0.66 ng/mL). 
Patients with the intermediate metabolizer (IM) and NM phenotypes had hydromorphone plasma 
concentrations between the values reported for UMs and PMs (4.29 and 5.73 ng/ml, respectively).  
Impact of Genetic Polymorphisms on Response to Hydrocodone 
The influence of polymorphisms in OPRM1 on pain response was assessed in the study by 
Boswell et al.
(27)
 Female patients who underwent cesarean section were treated with 
hydrocodone/acetaminophen (5 mg/325 mg or 7.5 mg/325 mg) every 4 hours as needed for 
postoperative pain relief after receiving IV or intrathecal morphine for the first 24 hours after surgery. 
There was a significant association between pain scores and hydrocodone total daily dose, as well as 
hydromorphone plasma concentration (the active metabolite of hydrocodone), in patients with the AA 
genotype (118 A>G) for OPRM1. However, this relationship did not reach statistical significance in 
patients carrying either one or two copies of the G variant allele. This finding could most likely be 
ascribed to the small number of patients with the GG genotype (n=5) enrolled in the study. 
Furthermore, there was no direct comparison of the differences in hydrocodone daily doses between 
patients with the AA versus the AG and GG genotypes. Besides OPRM1, polymorphisms in CYP2D6 had a 
significant impact on the analgesic effects of hydrocodone as demonstrated in the study by Stauble et al 
(21). High plasma concentrations of hydromorphone as a result of functional CYP2D6 enzymes 
correlated with pain relief in female patients after cesarean section. Furthermore, hydromorphone 
concentration was the only significant predictor of pain response to hydrocodone in multiple regression 
analysis after adjusting for age, body mass index, and duration of treatment (p=0.023).  
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Impact of Genetic Polymorphisms on Hydrocodone Toxicity Profile 
The evidence on the relationship between genetic polymorphisms and hydrocodone adverse 
effects is quite scant. Madadi et al. reported a case of respiratory depression with hydrocodone that 
tragically resulted in the death of a 5-year-old child.
(28)
 
 Nevertheless, the child was also receiving 
clarithromycin for ear infection, thereby raising the critical question of whether the underlying etiology 
of her lethal hydrocodone plasma concentration was due to her CYP2D6 genotype (*2/*41) or the 
concomitant treatment with clarithromycin, a potent inhibitor of the CYP3A4 pathway involved in 
hydrocodone metabolism.  
Clinical Adoption of Hydrocodone Pharmacogenetics 
According to the CPIC guideline for codeine, hydrocodone may not a good alternative to codeine 
in CYP2D6 UMs and PMs. These CPIC recommendations are mainly based on the fact that hydrocodone 
is a CYP2D6 substrate and not on particularly robust evidence. Given the lack of evidence, more 
research is warranted to further elucidate the relationship between genetic polymorphisms in CYP2D6 
or OPRM1 and response to hydrocodone. In all, the evidence and the CPIC comments surrounding 
hydrocodone pharmacogenetics places it in the “further research needed” category when considering 
clinical actionability, as depicted in Figure 2.  
 
Methadone 
Impact of Genetic Polymorphisms on Methadone Disposition 
Methadone exists as a racemic mixture of R- and S-enantiomers, with the former having at least 
a 10-fold greater affinity for the μ receptors than the latter. The CYP2B6 metabolic pathway represents 
the major route of methadone elimination or clearance. Similar to other CYP enzymes , the gene coding 
for CYP2B6 is highly polymorphic, with more than 38 variants identified thus far, which primarily arise 
from SNPs.
(29)
 The prevalence of each CYP2B6 allele varies among different populations (Table 1). The 
CYP2B6*6 (516 G>T, 785 A>G) is by far the most studied variant given its high prevalence among various 
racial groups. Several studies (including ex vivo studies) were able to identify CYP2B6 as a significant 
genetic determinant of the variability in methadone elimination.
30( , 31)
 Moreover, Kharasch conducted a 
pharmacokinetic study where 128 healthy volunteers were given simultaneously IV racemic methadone 
hydrochloride 6 mg (5.4 mg of free base) and labeled oral methadone hydrochloride 11 mg (9.86 mg of 
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free base).
(32)
 For IV methadone, the S-enantiomer clearance (mL/kg/min) was significantly lower in 
patients with the CYP2B6*1/*6 (1.2 ± 0.4) and CYP2B6*6/*6 (0.96 ± 0.33) genotypes compared to those 
who had the CYP2B6*1/*1 (1.5 ± 0.3) genotype (p<0.05). The R-enantiomer clearance did not 
significantly differ by CYP2B6 genotype. For oral methadone, the clearances of both the R- and the S-
enantiomers were significantly different in *6 carriers in comparison with *1 homozygotes. In addition 
to the CYP2B6*6 variant, the authors investigated the influence of other CYP2B6 variants on the 
pharmacokinetic profile of methadone. Contrary to the findings with the CYP2B6*6 allele, the presence 
of the CYP2B6*4 variant resulted in increased methadone clearance, whereas the CYP2B6*5 allele had 
no impact on methadone clearance.
32( )
 As represented in Table 2, ABCB1 and CYP3A4 have been shown 
to influence methadone pharmacokinetics as well.
31( )
 
 
Impact of Genetic Polymorphisms on Methadone Response 
There is a significant lack of data relating polymorphisms to clinical response outside of 
methadone maintenance therapy.  
 
Impact of genetic polymorphisms on Methadone Toxicity Profile 
 Currently, to our knowledge, there are no data published on the toxicity profile of methadone 
relative to genetic polymorphisms in patients with pain. 
 
Clinical Adoption of Methadone Pharmacogenetics 
Further research is needed in methadone pharmacogenetics particularly to explore the 
relationship between genetic polymorphisms and analgesic response to methadone, as well as adverse 
effects. To date, there is insufficient evidence to support the clinical implementation of 
pharmacogenetic testing for patients with pain treated with methadone (Figure 2). 
 
Morphine 
Impact of Genetic Polymorphisms on Morphine Disposition 
The principal pathway involved in morphine metabolism is conjugation to morphine-6-
glucuronide (M6G, which accounts for 60% of all metabolites) and morphine-3-glucuronide (M3G). 
These reactions are mediated mainly by the UGT2B7 phase II enzyme in the liver.
(33)
 UGT1A1 plays a 
minor role in the glucuronidation of morphine to M3G. Polymorphisms in phase II enzymes have also 
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been studied for association with variability in morphine exposure. Of special interest is the UGT1A1*28 
polymorphism, which results from seven tandem repeats of the dinucleotide TA.
(34, 35)
 Accordingly, the 
presence of these polymorphisms confers reduced enzymatic activity of UGT1A1 attributable to 
reduced expression of the enzyme (~8-fold reduction). In the study by Holthe et al., the glucuronidation 
products to morphine plasma ratios were compared among 70 patients with cancer based on UGT 
polymorphisms.
33
 Findings from this study indicated that the plasma ratios were comparable among 
patients homozygous for the UGT1A1*28 variant, carriers of this variant, and those who were 
homozygous for the wild-type allele (M6G/morphine ratios 7.1 ± 4.1, 7.4 ± 6, and 7.1 ± 3.9, respectively, 
and M3G/morphine ratios 38 ± 20.8, 40.8 ± 28.5, and 34.4 ± 19.4, respectively). Furthermore, the 
effects of UGT2B7 polymorphisms were similar to those observed with the UGT1A1*28 variant. On the 
other hand, the study by Darbari et al. demonstrated that polymorphisms in UGT2B7 could modulate 
the AUC of morphine and its metabolites.
36( )
 
 The study included 20 patients with sickle cell disease 
treated with a single IV dose of morphine 0.1 mg/kg infused over 30 minutes. Blood samples were 
collected to measure morphine, M3G, and M6G concentrations before, at the end, and at several time 
points after the infusion. Additionally, UGT2B7 was genotyped for two SNPs, -840 G>A (rs7438135) and 
-79 G>A. The authors noted that carriers of the G variant (GA/GG genotypes) for rs7438135 (-840 G>A) 
had significantly lower M3G/morphine and M6G/morphine AUC ratios compared to patients with the 
AA genotype (for M6G/morphine: 1.8 ± 0.5 vs. 3.0 ± 1.8, p=0.03; for M3G/morphine: 10.1 ± 2.7 vs. 15.7 
± 9.4, p=0.05).  
Impact of Genetic Polymorphisms on Response to Morphine 
Results from several studies demonstrated that the presence of the G variant of OPRM1 
(rs1799971) confers reduced analgesic effects on treatment with morphine. In the study by Gong et al, 
which enrolled 112 patients with cancer treated with opioids for pain relief, the morphine equivalent 
daily dose needed to achieve adequate analgesia, which the authors defined as the dose needed to 
reduce the pain score (using a visual analogue scale) to ≤4, was significantly lower among patients with 
the AA genotype compared with those carrying the G variant (AA: 72.4 ± 64 mg, AG: 97.3 ± 69 mg, and 
GG: 152.3 ± 83 mg, p=0.005).
(37)
 Polymorphisms in ABCB1 (3435 C>T) did not contribute to the 
variability in morphine doses observed among patients. In the same context, Klepstad et al. 
interrogated the influence of OPRM1 polymorphisms on morphine daily doses in patients with cancer 
who reported adequate pain relief using the brief pain inventory (BPI ≤4). Of the 207 patients included 
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in their final analysis, 17 (8%) were heterozygous for the variant G allele (118 A>G), and only four were 
homozygous (2%) for the G polymorphism.
(38)
 Patients with the GG genotype for OPRM1 required 
significantly higher daily doses of morphine to achieve satisfactory pain control in comparison to 
patients homozygous for the wild-type, A allele (GG: 225 ± 143 mg/day vs. 97 ± 89 mg/day among 
patients with the AA genotype for OPRM1, p=0.006). Even after adjusting for other confounding factors 
such as age, tumor location, performance status, and time from start of morphine, the effects of 
OPRM1 polymorphisms on morphine requirements remained significant and independent of other 
covariates. Of note, the difference in morphine daily doses did not reach statistical difference between 
carriers of the G allele and those homozygous for the wild-type, A allele (66 ± 50 mg/day vs. 97 ± 89 
mg/day).  Reyes-Gibby et al. evaluated the joint effect of polymorphisms in both pharmacodynamics 
genes, OPRM1 and COMT, on morphine daily dose requirements among patients with cancer.
39( )
Several studies were also conducted primarily in the postoperative setting to discern the effects 
of OPRM1 polymorphisms with regard to opioid/morphine consumption for analgesia. In the study by, 
et al., 138 patients who underwent open abdominal surgery (gastrectomy, colectomy, hepatectomy and 
pancreaticoduodenectomy) received continuous epidural analgesia with fentanyl or morphine.
 
Patients with the A/A and the Met/Met genotypes for OPRM1 (118 A>G) and COMT (Met158Met) 
required significantly lower morphine doses (87 mg/day, 95% CI 57-116) for pain relief compared to 
patients with the other OPRM1 and COMT genotypes (147 mg/day, 95% CI 100-180, p<0.012).  
(24)
 The 
distribution of the OPRM1 genotypes for the 118 A>G SNP was 41 (29.7%) for AA, 70 (50.7%) for AG, 
and 27 (19.6%) for GG. The 24-hour postoperative opioid dose requirement was significantly higher in 
patients with the GG genotype compared to patients with the AG and the AA genotype for OPRM1 
(p<0.05). The results of the study by Chou et al, which included 120 patients undergoing total knee 
arthroplasty, lend further support to the role of OPRM1 polymorphisms.
40( )
Although the results of these studies provide a plausible explanation for the interindividual 
variation in opioid dose requirements in relation to OPRM1 polymorphisms, some studies failed to 
establish such a causal relationship between these two. As an example, the studies by Coulbault et al. 
 Patients with the GG 
genotype (n=11, 11%) consumed significantly larger amounts of parenteral morphine 24 and 48 hours 
after surgery to achieve adequate pain control compared to patients with the AA and the AG genotypes 
(p <0.05). The difference in morphine doses between patients with the AG and the AA genotypes was 
not statistically significant.  
(41)
 and Klepstad et al. 
42( )
 showed no significant association between the 118 A>G polymorphism and 
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morphine dose requirements. It is important to point out that the studies were most likely 
underpowered to detect a difference in morphine consumption given the low frequency of the GG 
genotype for OPRM1 (118 A>G).  
Unlike polymorphisms in OPRM1, there is a paucity of evidence linking COMT to interindividual 
variation in opioid dose requirements. Among patients with cancer treated with morphine for pain 
relief, Rakvag et al. noted that patients harboring the Val/Val (GG) genotype (rs4680, G>A) required 
significantly higher mean daily doses of morphine for adequate analgesia compared to the other 
genotypes of COMT (Val/Val: 155 ± 160 mg/24 hours, Val/Met: 117 ± 100 mg/24 hours, and Met/Met: 
95 ± 99 mg/24 hours, p=0.02).
(43)
 These results were further replicated in another study by Rakvag et al, 
in which the authors detected significant differences in the daily doses of morphine based on rs4680 
(Val158Met) genotypes.
44( )
 
 The median morphine daily doses for rs4680 (Val158Met) were 90 mg, 80 
mg, and 60 mg for the GG (Val/Val), GA (Val/Met) and the AA (Met/Met) genotypes, respectively 
(p=0.022). Moreover, there was a significant difference in the median morphine daily doses based on 
the presence of the rs4818 (C>G) SNP in COMT (CC: 60 mg/24 hours, CG: 80 mg/24 hours, and GG: 120 
mg/24 hours, p=0.042). In addition to these two polymorphisms in COMT, other less studied SNPs were 
interrogated. Nonetheless, none was significantly associated with morphine daily dose requirements. 
The authors of this study also constructed COMT haplotypes for each patient based on his or her 
genotype information. Interestingly, one of the haplotypes that contained the rs4680 SNP (A>G) was a 
significant determinant of the variability in morphine daily doses (median morphine dose 60 mg for 
patients carrying this haplotype vs. 100 mg for those not carrying it, p=0.006).  
Impact of Genetic Polymorphisms on Morphine Toxicity Profile 
The impact of ABCB1 genetic polymorphisms on patient outcomes was explored in a study of 
273 children undergoing tonsillectomy in which morphine was administered perioperatively.
(45)
 It was 
determined that the ABCB1 variant rs9282564 was associated with a prolonged postoperative 
anesthesia care unit stay due to respiratory depression (p=0.0002). Statistical significance of this 
association was upheld when the subjects were stratified into race cohorts (white and black). Patients 
with GG and GA genotypes of rs9282564 experienced greater risks of respiratory depression, and it was 
determined that one copy of the G allele carried a 5-fold increased odds of prolonged stay due to 
respiratory depression.  
Au
th
or
 M
an
us
cr
ip
t
15 
 
This article is protected by copyright. All rights reserved 
Again, in a case report, two patients who received morphine and experienced adverse effects 
were genotyped for 20 functional polymorphisms.
(46)
 
 The first patient received perioperative morphine. 
Approximately 15 hours postoperatively, the patient had a respiratory rate of 4 breaths per minute and 
was not responding to painful stimuli. She was determined to have a CYP2D6*2/*2 genotype, indicating 
normal CYP2D6 activity, but a UGT2B7 C802T TT genotype (rs7439366) may have led to an increase in 
morphine-6-glucuronide formation. The patient had a COMT haplotype TCA (rs4633, rs4818, rs4680) 
that may have led to an increase in opioid sensitivity. The second case report described a patient who 
received intraoperative morphine and became unresponsive in the recovery room. The patient was 
genotyped and found to have mutations in ABCB1 haplotype TTT (rs1128503, rs2032582, rs1045642) 
and COMT haplotype CCG (rs4633, rs4818, rs4680) that may have led to increased morphine exposure 
and opioid sensitivity. This patient also had an OPRM1 polymorphism rs1799971 (G/G), which is 
associated with increased morphine requirements, so the clinical outcomes of each polymorphism in 
this case are difficult to ascertain.  
Clinical Adoption of Morphine Pharmacogenetics 
Despite being the prototype of all opiate analgesics, guidelines supporting pharmacogenetic 
testing to help guide morphine dose selection are currently lacking; this is partly explained by the 
controversy in the literature particularly that surrounding the role of OPRM1, which, in principle, seems 
to be a reasonable genetic marker worth pursuing. Nonetheless, the morphine-OPRM1 association is 
moderately actionable due to the relative level of evidence currently available for this pair in 
comparison to all the other genes associated with other opioids and outcomes (Figure 2).   
 
Oxycodone 
Impact of Genetic Polymorphisms on Oxycodone Disposition 
Oxycodone is semisynthetic opioid that is generally prescribed for management of moderate to 
severe nociceptive pain. Although it is also structurally related to codeine, oxycodone has analgesic 
properties by activation of the μ receptors. Whereas CYP3A4/5 is the principal metabolic pathway 
involved in converting oxycodone to noroxycodone (accounting for more than 50% of the overall 
metabolic pathway), the CYP2D6 metabolic pathway plays a minor role. However, it is worth noting that 
the latter pathway (CYP2D6) is responsible for converting oxycodone to a more potent analgesic, 
oxymorphone.   
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To our knowledge, the study by Naito et al. is the only study reported in the literature that 
sought to evaluate the differences in oxycodone, noroxycodone, and oxymorphone plasma 
concentrations based on polymorphisms in CYP3A5.
(47)
There is a large body of evidence to suggest variation in oxymorphone plasma concentration 
according to CYP2D6 polymorphisms. Andreassen et al. conducted a cross-sectional study to evaluate 
the influence of CYP2D6 polymorphisms on the pharmacokinetics of oxycodone.
 Sixty-two patients with cancer treated with 
extended-release oxycodone 5 mg every 12 hours were enrolled in the study; 37 (60%) were 
homozygous for the CYP3A5*3 variant or the loss of function allele (i.e., CYP3A5 nonexpressers). 
Interestingly, polymorphisms in CYP3A5 had no significant impact on the mean plasma concentration of 
oxycodone (121 ng/mL among carriers of CYP3A5 *3/*3 vs 113 ng/mL among carriers of CYP3A5*1, 
p=0.62). Nonetheless, there were significant differences in noroxycodone and oxymorphone 
concentrations based on polymorphisms in CYP3A5 and CYP2D6, respectively. The median plasma 
concentration of noroxycodone (the major metabolite of oxycodone) was 54.8 ng/ml (IQR 36-94.6) in 
patients homozygous for CYP3A5*3 as opposed to 99.7 ng/ml (IQR 58.6-140) among CYP3A5*1 carriers 
(p=0.01). These observed differences in noroxycodone plasma concentrations translated into significant 
differences in the ratio of noroxycodone to oxycodone (0.63 [IQR 0.15-0.87] ng/mL for CYP3A5*3/*3 vs 
0.92 [IQR 0.56-1.25] ng/mL for CYP3A5*1/*1 and *1/*3, p<0.01).  
(48)
 The study included 
450 patients with cancer who were receiving oxycodone for analgesia, of whom 6%, 92%, and 2% had 
the PM, NM, and UM phenotypes, respectively. The plasma concentrations of oxymorphone differed 
significantly between PMs and UMs, as well as between PMs and NMs (p<0.0001). Furthermore, the 
authors also detected the same trend in the oxymorphone/oxycodone ratio (0.0028 for PMs, 0.0172 for 
NMs, and 0.0244 for UMs) where the difference was also significant between PMs and UMs, as well as 
PMs and NMs (p<0.05). The study by Zwisler et al. set out to determine whether CYP2D6 regulates 
oxycodone exposure among patients undergoing surgery.
49( )
 Following surgery, patients received 
oxycodone for 24 hours in addition to morphine (for breakthrough pain). In line with the results 
reported in the previous study,
48
In the study by Naito et al, with 62 patients receiving extended-release oxycodone 5 mg every 12 
hours for the management of cancer pain, 16 (26%) had the CYP2D6 IM phenotype.
 PMs had significantly lower plasma concentrations of oxymorphone, 
compared with those of EMs. Alternatively, oxycodone plasma concentrations were almost the same 
among the different CYP2D6 metabolizer phenotypes.  
47
 Although the 
plasma concentrations of oxycodone were comparable (126 ng/mL for CYP2D6 IMs vs 103 ng/mL for 
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NMs, p=0.3), the authors noted more than a 50% reduction in the plasma concentrations of 
oxymorphone among patients with the IM phenotype compared to those with the NM phenotype (0.79 
ng/mL, IQR 0.34-1.6 vs. 1.69 ng/mL, IQR 0.79-3.39, p=0.02). Additionally, the oxymorphone to 
oxycodone ratio was significantly lower in patients with the CYP2D6 IM phenotype compared to those 
with the CYP2D6 NM phenotype (0.0072, IQR 0.004-0.0128 vs. 0.012, IQR 0.007-0.027, p=0.04).  
Finally, in a prospective observational study of 121 patients who underwent abdominal surgery 
or thoracotomy, Samer and colleagues reported significant differences in oxymorphone/oxycodone 
ratios by CYP2D6 metabolizer phenotype: PMs: 0.1 (95% CI 0.02-0.19), IMs: 0.13 (95% CI 0.11-0.16), 
NMs: 0.18 (95% CI 0.16-0.2), and UMs: 0.28 (95% CI 0.07-0.49) (p=0.001).
(50)
 
 Post hoc analysis indicated 
that a significant difference occurred between PMs and UMs (p=0.009), as well as IMs and UMs 
(p=0.005).  
Impact of Genetic Polymorphisms on Response to Oxycodone 
The influence of OPRM1 polymorphisms on oxycodone dose requirements was evaluated in a 
study by Cajanus et al. among 993 patients with nonmetastatic breast cancer who elected to undergo 
mastectomy or breast-conserving surgery.
(51)
Another study by Zwisler et al. showed that there was no association between OPRM1 
polymorphisms and the analgesic effects of oxycodone.
 Postsurgical pain was assessed using the numerical rating 
scale (NRS), and oxycodone 1-3 mg was administered until the patients reported a pain intensity score 
of less than 4 on this scale. Patients with the GG genotype (118 A>G) required the highest doses of 
oxycodone (0.16 mg/kg) to achieve an adequate state of analgesia compared to patients with the AG 
(0.13 mg/kg) and the AA (0.12 mg/kg) genotypes (p<0.0001).  
(52)
 Initially, 268 adult patients received IV 
oxycodone 5 mg 30 minutes prior to the end of surgery (thyroidectomy, parathyroidectomy, 
mastectomy, or hysterectomy). This was followed by a 5-mg IV dose administered in the recovery room, 
which was repeated if the pain score using the NRS remained above 4 following the first postoperative 
oxycodone dose. According to protocol, all patients received acetaminophen (paracetamol) 1000 mg 
every 6 hours along with 50 mg diclofenac every 8 hours for postsurgical pain management. Pain 
response rates based on polymorphisms in OPRM1 were 83.7% and 83% for the AA and AG/GG 
genotypes, respectively (p=1). It is important to point out that the administration of around-the-clock 
doses of acetaminophen and diclofenac raises some concerns as to whether these medications did, in 
fact, obscure the effect of OPRM1 polymorphisms on pain response to oxycodone in surgery patients. 
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Moreover, the study by Naito et al. (described earlier) detected similar findings (i.e., no significant 
differences in oxycodone doses based on OPRM1 polymorphisms [118 A>G]).
(47)
Given the role of CYP2D6 in oxycodone metabolism, Zwisler et al evaluated the impact of this 
pharmacokinetics gene (CYP2D6) on postoperative pain response to oxycodone in 270 adult patients.
 Nonetheless, the 
prevalence of patients with the GG genotype (118 A>G) for OPRM1 was not reported in the study since 
patients carrying at least a single G variant were all grouped together as a single group.  
(49)
 
 
At the end of the study, the authors detected no significant difference in the 24-hour consumption of 
oxycodone between NMs (14.7 mg, CI 13.0 - 16.4) and PMs (13.0 mg, CI 8.9 - 17.0, p=0.42)  
Impact of Genetic Polymorphisms on Oxycodone Toxicity Profile 
In the study by Andreassen et al (described earlier), the higher plasma concentrations of 
oxymorphone in patients with the CYP2D6 UM phenotype did not result in higher rates of adverse drug 
events such as tiredness and nausea. 
(48)
 
 
Clinical Adoption of Oxycodone Pharmacogenetics 
Similar to most opioid analgesics, treatment with oxycodone is also based on a trial and error 
approach. In light of its widespread use for pain management, there is definitely an unmet need for 
optimizing response to oxycodone. Nonetheless, it is rather challenging to discern whether genetic 
polymorphisms have any impact on response to oxycodone given the complicated metabolic pathway 
that the drug undergoes and the fact that the parent drug itself has some intrinsic analgesic effects 
(unlike tramadol and codeine). Hence, until more evidence becomes available, it is most likely that 
oxycodone dosing and/or selection will remain empiric for managing pain. Furthermore, the codeine 
CPIC guideline recommends against the use of oxycodone as an alternative to codeine in CYP2D6 UMs 
and PMs. Collectively, the body of knowledge surrounding oxycodone and CYP2D6 suggests that this 
drug-gene pair’s clinical actionability potential is weak at best; hence, further studies are needed (Figure 
2). 
 
Tramadol 
Impact of Genetic Polymorphisms on Tramadol Disposition 
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Tramadol is a prodrug, which exists as a racemic mixture of R- and S-enantiomers. Its analgesic 
properties reside in its active metabolite, O-desmethyltramadol (ODT). Tramadol bioactivation to ODT 
occurs in the liver via the CYP2D6 enzyme. In the study by Stamer et al., 187 patients who underwent 
abdominal surgery were genotyped for CYP2D6 polymorphisms in order to assess the relationship 
between tramadol disposition and the various CYP2D6 metabolizer phenotypes.
(53)
 Approximately 90 
minutes prior to anesthesia termination, patients were given an IV loading dose of tramadol 3 mg/kg. Of 
the 187 patients, 68 (36%), 18 (10%), and 8 (4%) were NMs, PMs, and UMs, respectively. PMs had the 
lowest AUC for ODT (0 ng.hr/mL, IQR 0-11.4), which differed significantly from those for IMs (38.6 
ng.hr/mL, IQR 15.9-75.3), NMs (66.5 ng.hr/mL , IQR 17.1-118.4), and UMs (149.7, IQR 35.4-235.4) 
(p<0.001). In another study by Pedersen et al., 16 healthy participants (8 NMs and 8 PMs) received a 
single oral dose of tramadol 150 mg in the first phase of the study.
54( )
 In the second phase, participants 
were given tramadol 50 mg orally 3 times a day for 48 hours, whereas in the third phase of the study, a 
single IV dose of tramadol 100 mg was administered to all participants. The authors sought to compare 
the differences in tramadol pharmacokinetics between the two CYP2D6 metabolizer phenotypes (NMs 
and PMs). In each of the three phases, the AUC of the active metabolite was at least 6-fold lower in 
patients with the PM phenotype (p<0.0001). Findings from the study by Gan et al. indicated that 
tramadol clearance varies with CYP2D6 phenotypes.
65
 
 Patients with the IM phenotype had lower 
tramadol clearance (16 L/hr) compared to those with the UM phenotype (42 L/hr). Subsequently, the 
half-life of tramadol was approximately 2-fold longer in IMs relative to UMs (3.8 vs 7.2 hrs).  
Impact of Genetic Polymorphisms on Response to Tramadol 
Tramadol requires bioactivation in the liver in order to exert its analgesic effect. Because this 
process is mediated primarily by CYP2D6, it is only reasonable to assume that polymorphisms in CYP2D6 
influence response. Indeed, the study by Stamer et al. (described earlier) revealed that tramadol 
consumption at 48 hours after surgery was significantly higher among patients with the CYP2D6 PM 
phenotype (p=0.002).
53
 
 Additionally, almost 81% of the PMs failed to have an adequate response to 
tramadol, defined as an NRS pain score < 40 at 48 hours after surgery (p<0.001). These data suggest 
that tramadol may not be an appropriate analgesic for patients with the CYP2D6 PM phenotype.  
Impact of Genetic Polymorphisms on Tramadol Toxicity Profile 
Au
th
or
 M
an
us
cr
ip
t
20 
 
This article is protected by copyright. All rights reserved 
A single case report exists that describes respiratory depression in a patient with the CYP2D6 
UM phenotype receiving tramadol by patient-controlled analgesia device.
(55)
 The patient had baseline 
renal dysfunction and was undergoing scheduled surgery for renal carcinoma. Respiratory depression 
was noted 10.5 hours after the procedure and was successfully treated with naloxone. Moreover, the 
FDA issued a safety announcement for tramadol in April 2017 contraindicating the use of tramadol in 
individuals younger than 18 years of age following tonsillectomy or adenoidectomy surgeries.
21( )
 
 The 
new warning also states that tramadol is contraindicated in children younger than 12 years for pain 
relief as well as adolescents (between 12 and 18 years of age) who are either obese, have obstructive 
sleep apnea, or have severe lung disease. Furthermore, the FDA cautions against the use of tramadol in 
nursing mothers due to the potential risk of serious adverse reactions including respiratory depression 
and even death. Although the FDA did not recommend CYP2D6 testing prior to initiating tramadol, their 
statement suggests variability in tramadol’s metabolism, which is mostly likely attributed to CYP2D6 
polymorphisms.  
Clinical Adoption of Tramadol Pharmacogenetics 
According to the guidelines set forth by the CPIC, opioid analgesics that do not undergo hepatic 
metabolism via the CYP2D6 pathway are recommended as alternatives to tramadol for patients with 
the PM and UM phenotypes, and tramadol use in patients with CYP2D6 IM phenotype should be 
monitored closely for response.
(20)
 
 Hence, these guidelines support the clinical utility of CYP2D6 
genotyping in routine clinical practice as a tool to identify the subset of patients (i.e., CYP2D6 NMs) who 
are more likely to benefit from tramadol when used for pain management (Figure 2). 
Implementation of Opioid Pharmacogenetics in Clinical Practice 
Pain management is critical in clinical practice because uncontrolled pain can delay healing, 
decrease appetite, introduce and augment stress, disturb sleep, and may even lead to anxiety and 
depression. As such, effective pain treatment regimens are necessary to improve quality of life. As 
documented in studies described throughout this review, opioids, although widely used, do not produce 
optimal analgesia for all patients. Nevertheless, personalization of opioid selection and dosing is not 
widely practiced. This is likely a reflection of the relative paucity of data regarding clinical outcomes and 
opioid pharmacogenetics.  Currently, CPIC guidelines are available for codeine and CYP2D6.
(20)
 Tramadol 
is not an appropriate alternative to codeine in CYP2D6 UMs and PMs or IMs who have failed codeine 
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therapy due to tramadol’s reliance on CYP2D6 for bioactivation. Opioids not metabolized by CYP2D6, 
such as morphine, hydromorphone, oxymorphone, buprenorphine, fentanyl, methadone, and 
hydromorphone, and other nonopioid analgesics should be considered instead. Due to the 
pharmacologic similarities of codeine and tramadol (both exert their analgesic properties from their 
CYP2D6 metabolites), and the consistency of the supporting evidence, the CYP2D6-guided therapeutic 
recommendations for codeine can be extrapolated to tramadol in practice. 
With the exception of codeine and tramadol, the current body of literature does not strongly 
support clinical adoption of pharmacogenetics for other opioids. As such, clinicians should closely 
evaluate clinical pharmacogenetics panel test results, particularly those providing guidance for 
genetically guided pain management. As reviewed in this article, supportive evidence is lacking for 
majority of these drug-gene associations. 
To the best of our knowledge, only a handful of institutions in the United States have actually 
adopted CYP2D6 genotyping to guide codeine/tramadol usage. Such establishments include, but are not 
limited to, The Mount Sinai Hospital, St. Jude Children’s Research Hospital, University of Florida, Sanford 
Health, Indiana University, and Moffitt Cancer Center. Challenges comprising limited pharmacogenetics 
knowledge base of practicing clinicians, complexity of CYP2D6 genotyping, lack of reimbursement for 
genetic testing, lack of supportive institutional infrastructure, lack of randomized controlled trials 
demonstrating benefit of CYP2D6-guided prescribing, and availability of other analgesics that are not 
affected by pharmacogenetics have all contributed greatly to the slow adoption of personalized pain 
management.  
 
Summary and Future Directions 
The goal of pharmacogenetics as a clinical tool in opioid therapy is to optimize pain relief and 
prevent adverse effects. When pharmacogenetics is coupled with clinical factors such as age, weight, 
renal and hepatic function, concomitant medications, personalized pain management can be actualized. 
However, to date, the evidence is not compelling enough for widespread clinical adoption of opioid 
pharmacogenetics.  
In the cases of codeine and tramadol, there are many case reports that have revealed consistent 
and persuasive evidence of the significant impact of CYP2D6 polymorphisms on serious adverse effects 
including respiratory depression and death. This association caught the attention of the FDA in August 
2012 when they issued a safety announcement to health care professionals. In February 2013, they 
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issued their strongest warning—a boxed warning—which made codeine contraindicated in post-
adenoidectomy/tonsillectomy pain management of children.
(56)
With the exception of codeine and tramadol, morphine-OPRM1, oxycodone-CYP2D6, and 
hydrocodone-CYP2D6 may be the closest cases to clinical implementation, in descending order, due to 
their supporting evidence and recommendations from expert peer-reviewed CPIC guidelines. 
Hydrocodone is one of the least-studied opioids in pharmacogenetics, and further studies are 
warranted with this agent. On the other hand, methadone has been well studied, although with varying 
genetic targets and for nonpain indications.  Fentanyl is in the same space as methadone, as more 
studies are needed to clearly elucidate the influence of genetics on its response. The “clinical adoption” 
sections throughout this article highlight the gaps in the literature for each of these examples and state 
what is needed to translate each opioid-gene pair into clinical practice. Moreover, studies that 
investigate the combined effects of multiple genes on opioid disposition, response, and adverse events 
are critically needed. These studies will provide heightened insight into these genetic associations and 
will enhance the use of pharmacogenetics as a therapy personalization tool in medicine. 
 Additionally, the codeine-CYP2D6 
example is the only opioid-gene instance with a CPIC guideline.  
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Table 1. Commonly Studied Variant Alleles of Pharmacokinetics and Pharmacodynamics Genes and 
Their Prevalence Across Different Populations
a
Gene  
 
 
Variants  
Prevalence of Variants (%) 
Functional 
Status Caucasians         
African-
Americans Asians 
CYP3A4 *22: rs35599367 (intron 6 C>T)       Reduced function 
CYP3A5 
*3: rs776746 (6986 T>C) 92.1 31.6 74.2 Loss of function 
*6: rs10264272 (14690 C>T) 0 11.1 0 Loss of function 
*7: rs41303343 (27131 - 27132 
insertion A) 0 12 0 Loss of function 
CYP2B6 
*4: rs2279343 (18053 A>G) 4 0 5 - 12 Enhanced function 
*5: rs3211371 (25505 C>T) 9 - 12 1 - 4 1 - 4 Reduced function 
*6: rs3745274 (15631 G>T), 
rs2279343 (18053 A>G) 14 - 27 33 - 50 20 - 21 Reduced function 
*18: rs28399499 (21011 T>C) 0 4 - 8 0 Reduced function 
*22: rs34223104 (-82 T>C) 2.4  0 - 2.5 0 - 2.5 Enhanced function 
CYP2D6 
*2: rs16947 (2850 C>T), rs1135840 
(4180 G>C) 37 14 12.8 - 32 Normal function 
*3: rs35742686 (2549 deletion A) 1.3 1.3 0 Loss of function 
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*4: rs1065858 (100 C>T), rs3892097 
(1846 G>A), rs1135840 (4180 G>C) 18.5 6.2 0.4 - 6.5 Loss of function 
*5: gene deletion 2.6 6.14 2.5 - 5.6 Loss of function 
*6: rs5030655 (1707 deletion T) 1 0.2 0 Loss of function 
*10: rs1065852 (100 C>T), 
rs1135840 (4180 G>C) 3.1 4.1 19.7 - 42.3 Reduced function 
*17: rs28371706 (1023 C>T), 
rs16947 (2850 C>T), rs1135840 
(4180 G>C) 0.3 18.2 0.4 Reduced function 
*41: rs16947 (2850 C>T), 
rs28371725 (2988 G>A), rs1135840 
(4180 G>C) 8.5 9.4 2 - 10.5 Reduced function 
ABCB1 
rs2032582 (2677 G>T) 2 0 5 Reduced function 
rs1128503 (1236 C>T) 42 14 59 Reduced function 
rs2032582 (2677 T>A) 41 2 59 Reduced function 
rs1045642 (3435 C>T) 52 15 57 Reduced function 
rs9282564 (61 A>G) 8 0 2 Reduced function 
UGT1A1 
*6: rs4148323 (c. 211 G>A) 1 0 2 
Normal function 
(wild-type) 
*28: rs35350960 (c. -53-52 [TA]6 > 
[TA]7 31.6 ) 39.1 14.8 - 41.4 Reduced function 
*36: rs8175347 (c. -53 - 52 [TA]6 > 
[TA]5 0 ) 6.6 0 Enhanced function 
*37: rs815347 (c. -53 - 52[TA]6> 
[TA]8 0.1 ) 3.6 0 Reduced function 
UGT2B7 
*2: rs7439366 (c. 802 C>T) 49 23 40 Reduced function 
rs7438135 (-840 A>G) 49 23 40 Reduced function 
OPRM1 
rs1799971 (A>G) 15 - 30 1 - 3 40 - 50 
Impaired reception 
function 
COMT 
rs4680 (1947 G>A, Val158Met) 50 28 44 Reduced function 
rs4818 (C>G) 40 17 31 Reduced function 
 
a 
The frequencies for this table were referenced from the 1000 Gneomes Database Ensembl which is available via: 
http://grch37.ensembl.org/Homo_sapiens/Info/Index 
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Other information can be found here: http://www.cypalleles.ki.se/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Compilation of Relevant Studies on Opioids and Their Associated Genes of Interest  
Opioids 
Has Significant 
Genetic Influence on 
Drug Disposition 
Has Significant Genetic 
Influence on Response 
(Efficacy) 
Has Significant Genetic 
Influence on Adverse 
Drug Effects (Toxicity) 
Readiness for 
Clinical 
Adoption 
Yes No Yes No Yes No 
Codeine 
      ABCB1
(16)
     CPIC guidelines are 
currently available to 
guide CYP2D6-driven 
codeine therapy. In 
this guideline, 
codeine use is not 
recommended in 
CYP2D6 UMs and 
PMs due to potential 
risk of toxicity and 
lack of analgesic 
benefit, respectively. 
Also, CYP2D6 IMs 
who are prescribed 
codeine should be 
      COMT
(16)
      
CYP2D6
(57)
   
CYP2D6
(7, 13-
15)
CYP2D6
  
(16)
CYP2D6
  
(4, 6, 13, 
15, 17, 18)
  
  
    OPRM1
(16)
        
    UGT2B7
(16)
  
  UGT2B7   
(4) 
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monitored for 
response and 
switched to a 
different analgesic in 
the absence of 
analgesic benefit.  
Fentanyl 
    ABCB1
(5)
     ABCB1
(5) Not ready for clinical 
adoption due to lack 
of consistent data. 
Most associations 
are with OPRM1 and 
CYP3A5 
polymorphisms. 
 
      COMT
(22)
     
CYP3A5
(5)
         CYP3A5
(5)
  
OPMR1
(25)
   OPRM1
(23-25)
OPRM1 
(22)
     
Hydrocodone 
            Not ready for clinical 
adoption due to lack 
of compelling 
evidence to support 
its utility. However, it 
should be noted that 
hydrocodone is not 
an alternative to 
codeine in CYP2D6 
PMs and UMs. 
 
CYP2D6
(26)
     CYP2D6
(26)
CYP2D6   
(7) 
   
    OPRM1
(27)
  
     
Methadone 
ABCB1
(31)
    
  
    Not ready for clinical 
adoption; further 
research is needed. 
    
 
      
    
 
      
      
 
    
CYP2B6
(30-
32)
      
    
      
 
    
      
 
    
CYP3A4
(31)
            
      
 
    
    
  
    
    
 
      
      
 
    
    
  
    
            
Morphine     ABCB1
(58)
   ABCB1
(41, 45)
   Moderately 
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COMT
(39, 43, 
59)
      
  
actionable. The 
evidence supporting 
the influence of 
OPRM1 
polymorphisms on 
morphine therapy 
suggests that this 
opioid-gene pair may 
be considered for 
clinical adoption.  
 
 
. 
            
    
OPRM1
OPRM1
(24, 37-
40, 58-62)  
 
(41)
     
  UGT1A1
(33)
         
UGT2B7
(36)
UGT2B7  
(33)
  
       
Oxycodone 
      ABCB1
(52)
      Not ready for clinical 
adoption due to lack 
of consistently 
replicated evidence 
to support its utility. 
However, it should 
be noted that 
oxycodone is not an 
alternative to 
codeine in CYP2D6 
PMs and UMs. 
CYP2D6
(47-
50, 63)
  
  
CYP2D6
(7, 63, 
64)
CYP2D6 
(48, 49)
  
 
CYP2D6
(48)
  
CYP3A5
(47, 
50)
  
  
CYP3A5
(47)
  
      
    OPRM1
(51)
OPRM1  
(47, 52)
      
Tramadol 
CYP2D6
(53, 
54, 65)
  
  
CYP2D6   
(7, 53) 
 CYP2D6
(55, 65)
    
The CPIC guidelines 
for codeine 
comments on the 
relationship between 
CYP2D6 and 
tramadol and even 
postulates that 
tramadol is not a 
viable alternative to 
codeine in CYP2D6 
UMs, PMs, and those 
IMs who have failed 
initial codeine 
therapy. As such, 
CYP2D6 genotyping 
can be used to guide 
tramadol therapy. 
    OPRM1
(66)
       
CPIC = Clinical Pharmacogenetics Implementation Consortium; UM = ultrarapid metabolizer; PM = poor 
metabolizer; IM = intermediate metabolizer. 
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Figure 1. Metabolic pathways of opioid analgesics in the liver. CYP = cytochrome P450; UGT = uridine 
diphosphoglucuronysyltransferase. 
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Figure 2. Degree of readiness of opioids for clinical adoption based on evidence for specific opioid-gene 
pairs. Actionable = Clinical Pharmacogenetics Implementation Consortium guidelines are currently 
available to guide therapy individualization; moderately actionable = sufficient evidence exists to 
suggest clinical adoption, yet there are no expert peer-reviewed guidelines; further research needed = 
current evidence is weak at best, and there is no comment from expert peer-reviewed guidelines. 
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phar_1986_f1.pdf
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
Figure 2: Readiness of Opioids for Clinical Adoption 
 
 
Actionable: CPIC guidelines are currently available to guide therapy individualization;                                                                               
Moderately Actionable: Sufficient evidence exists to suggest clinical adoption yet there are no expert peer-reviewed 
guidelines.                                                                                                                                                                                                        
Further research needed: current evidence is weak at best and there is no comment from expert peer-reviewed 
guidelines.  
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